Balanced Risk-Reward After Soleno Acquisition Supports Neutral Stance on Neurocrine

In a report released yesterday, Sean Laaman from Morgan Stanley maintained a Hold rating on Neurocrine, with a price target of $173.00.

Sean Laaman has given his Hold rating due to a combination of factors tied to the Soleno acquisition and Neurocrine’s current profile. He views the purchase of VYKAT XR for Prader‑Willi syndrome as strategically sound, expanding Neurocrine’s rare endocrinology footprint and aligning well with its existing Crenessity commercial infrastructure, while being financed largely from cash with only a modest uptick in pre-payable debt.

At the same time, the valuation paid – effectively about $2.4B net of cash, equating to roughly 1.7x projected peak VYKAT XR sales – appears fair rather than clearly compelling, especially compared with higher multiples seen in recent rare‑disease transactions. Given Neurocrine’s increased dependence on successfully executing this rare‑disease launch, the decision not to pursue an EU filing, and the stock’s current trading level after the deal announcement, Laaman sees a balanced risk‑reward profile that supports maintaining a neutral, or Hold, stance.

In another report released yesterday, BMO Capital also maintained a Hold rating on the stock with a $140.00 price target.